In clinical Luminespib supplier situations when a fungicidal antifungal is desirable, AMB may be used. ”
“Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Clinic of Infectious Diseases, S’Orsola Malpighi Hospital, University of Bologna, Bologna, Italy Autopsy studies remain an essential tool for understanding the patterns of fungal disease not detected ante mortem with current diagnostic approaches. We collected data concerning the microbiological

trends, patient clinical characteristics and sites of involvement for invasive fungal infections (IFIs) identified at autopsy in a single large cancer treatment centre over a 20-year period (1989–2008). The autopsy rate and IFI prevalence both declined significantly during the study period. The prevalence of Aspergillus

spp. decreased significantly from the first 15 years of the study (from 0.12 to 0.14 cases per 100 autopsies to 0.07 in 2004–2008; P = 0.04), with only Mucorales accounting for a greater proportion of IFIs over the duration of the study period (0.06 to 0.2 cases per 100 autopsies, P = 0.04). After 2003, moulds accounted for the majority of infections identified at autopsy in the spleen, kidney, heart and STI571 datasheet gastrointestinal tract. Despite a trend of decreasing prevalence from 1989 to 2004, invasive candidiasis increased in prevalence during later periods 2004–2008 (0.02–0.05 per 100 autopsies) with decreasing kidney, heart and spleen involvement. Despite a declining autopsy rate, these data suggest a decreasing prevalence overall of IFIs with changing patterns of dissemination in patients with haematological malignancies. Invasive fungal infections (IFIs) remain an important cause of death in patients with leukaemia and recipients of haematopoietic stem cell transplantation (HSCT).[1-3] The epidemiology of IFIs has shifted over the past two decades, paralleling advances in treatment and transplantation for haematological

malignancies, earlier IFI diagnosis and the introduction of new antifungal agents into Carbohydrate clinical practice.[4-6] Since the 1990s, invasive aspergillosis has been the predominant IFI in patients with haematological malignancies,[1, 7] coinciding with the introduction and widespread use of fluconazole prophylaxis to reduce mortality associated with invasive candidiasis.[8] More recently, several cancer treatment centres have observed an increase in the prevalence of uncommon, but difficult-to-treat moulds such as Mucorales, Fusarium spp. and Phaeohyphomycetes.[3, 4, 6, 9, 10] The increase in these previously uncommon moulds has coincided with increasing antifungal resistance among Candida species[2, 11] and possibly also Aspergillus species.